Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Appointment of Non-Executive Director

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces that Peter M. Steinmann will be appointed to the Board as a Non-Executive Director with effect from 1 July 2013.

Peter, aged 50, is a Swiss national with over twenty years’ commercial experience in Medical Devices and Diagnostics. He has held senior roles within Johnson and Johnson, Medtronic International and Boehringer Mannheim. Most recently, he was Regional Vice President Global Surgery and Shared Services, Medical Devices and Diagnostics, Austria, Switzerland and Germany at Johnson and Johnson AG, Switzerland as well as Chairman of that Board. Having worked throughout Europe and North America, Peter has extensive knowledge of the global medical devices market.

Peter is currently a Non-Executive Director of Navus GmbH and is a Board Observer with Orthimo AG.

Commenting on the announcement, Dr Don Evans, Chairman of AMS, said:

“I am pleased to welcome Peter to the Board of AMS. His considerable commercial experience and deep knowledge of the global medical devices market, in particular the surgical sector, will be of great benefit as the Group continues to grow and expands into new markets.”

Peter Steinmann holds or has held directorships in the five years preceding his appointment at AMS as follows:

Current directorships:

Navus GmbH (Non-Executive Director)

Orthimo AG (elected Board Observer)

Past directorships

Director & Treasurer, Eucomed (European Medical Technology Association)

Chairman, Johnson & Johnson AG

Director, CARMAT s.a.s

Director, Medtronic (Schweiz) AG

There are no further disclosures to be made with regards to this appointment under paragraph (g) of Schedule 2 of the AIM Rules

– ends –

For further information, please visit www.admedsol.com or contact:

About Advanced Medical Solutions Group plc

Founded in 1991, AMS is a leader in the development and manufacture of innovative and technologically advanced products for the US$15 billion global wound care market. Through a mix of organic development and a number of acquisitions, AMS now has a wide range of products based on technologies that include alginates, silver alginates, foams, collagens, cyanoacrylate adhesives and sutures.

AMS manufactures wound care products for an extensive list of Original Equipment Manufacturer (“OEM”) customers around the world, but the majority of the Group’s revenues now come from its own brands – ActivHeal^® wound care products in the UK to the NHS, LiquiBand^® cyanoacrylate products primarily in the UK, Europe and the USA, and RESORBA^® sutures and collagen wound care products primarily in Europe. AMS develops innovative products from its R&D pipeline which it commercialises globally, either directly or through partnerships with its OEM customers.

AMS’s products are sold globally via a network of regional or multinational partners and distributors, as well as via AMS’s own direct sales forces in the UK, Germany, the Czech Republic and Russia.

With 450 employees operating under four distinct business units (Branded Direct, Branded Distributed, OEM and Bulk Materials) that match its multiple products and routes-to-market, AMS’s products are manufactured from two sites in the UK, one in the Netherlands, two in Germany and one in the Czech Republic.